Enhertu plus Perjeta shows a convincing progression-free survival benefit over a Perjeta triplet.

Bristol buys into the frenzy, and VEGF bispecific value inflation continues.

LY4170156 looks similar to Genmab’s rina-S, but cost Lilly a lot less.

Imdelltra seems headed for full approval, raising questions about Zai’s accelerated plan.

But camizestrant’s use could depend on uptake of monitoring – for now.

As patritumab-dxd's problems mount, Astra's decision to say no to this project looks smart.